Methods for treating juvenile idiopathic arthritis
AssigneeAbbVie Biotechnology Ltd.
InventorsJohn R. Medich, Susan K. Paulson, Peter A. Noertersheuser
Life of this patent
Estimating the term…
Abstract
The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNFα inhibitor.
Claims38
A method for treating polyarticular juvenile idiopathic arthritis in a subject comprising subcutaneously administering adalimumab to the subject every other week, wherein 20 mg of adalimumab is administered to the subject every other week if the subject weighs at least 15 kg and less than 30 kg, or wherein 40 mg of adalimumab is administered to the subject every other week if the subject weighs more than or equal to 30 kg.
A method for treating polyarticular juvenile idiopathic arthritis in a subject comprising subcutaneously administering adalimumab to the subject, wherein a mean steady state trough serum concentration of adalimumab is about 6 to 7 μg/mL or about 10 to 11 μg/mL,
- wherein 20 mg of adalimumab is administered to the subject if the subject weighs at least 15 kg and less than 30 kg, or wherein 40 mg of adalimumab is administered to the subject if the subject weighs more than or equal to 30 kg.
Dependencies are inferred from the claim text.